Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pidilizumab - CureTech

Drug Profile

Pidilizumab - CureTech

Alternative Names: CT-011; MDV 9300

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureTech
  • Developer American Cancer Society; Beth Israel Deaconess Medical Center; CureTech; Georgia Regents University; Hadassah Medical Organization; Northwestern University; The Ohio State University Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Delta like 1 protein inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Follicular lymphoma; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Phase I/II Glioma; Hepatitis C; Liver cancer
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma in India (IV)
  • 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma in Israel (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top